Table 2.
HFpEF characteristics and medications
Disease related characteristics | ||
NYHA class II | 10 (42%) | |
NYHA class III | 10 (42%) | |
NYHA class IV | 4 (17%) | |
Six min walk distance, m | 402 ± 42 | |
B-Type natriuretic peptide, pg/mL | 150 ± 26 | |
Diabetes | 10 (42%) | |
COPD | 2 (8%) | |
CAD | 6 (25%) | |
Hypertensive | 20 (83%) | |
Echocardiography | Value | Reference Range |
Ejection fraction, % | 62 ± 1 | ≥55 |
LV IVSD, cm | 1.1 ± 0.1 | 0.6 – 1.1 |
LV PWD, cm | 1.1 ± 0.1 | 0.6 – 0.9 |
LV ID diastole, cm | 4.5 ± 0.2 | 3.9 – 5.3 |
LV ID systole, cm | 3.0 ± 0.1 | 2.0 – 4.0 |
Peak E wave, cm/s | 84 ± 7 | -- |
Peak A wave, cm/s | 96 ± 11 | -- |
E/A ratio | 1.1 ± 0.2 | 0.6 – 1.32 |
E' lateral wall, cm/s | 7 ± 1 | 13–28 |
E/E' ratio | 13 ± 2 | ≤ 8 |
Mitral E-wave deceleration time, ms | 246 ± 14 | 142–258 |
Medications | ||
Beta receptor blocker | 11 (46%) | |
ACEi or ARB | 15 (63%) | |
Loop diuretics | 22 (92%) | |
Aldosterone antagonist | 16 (67%) | |
Statin | 18 (75%) | |
Nitrates | 5 (21%) | |
Calcium channel blockers | 3 (13%) |
HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association; LV IVSD, left ventricle interventricular septum diameter; LV PWD, left ventricle posterior wall diameter; LV ID, left ventricle internal diameter; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. Data are mean ± SEM or % of group.